139 related articles for article (PubMed ID: 36117998)
1.
Fang ZE; Guo Y; Wang Z; He T; Wang J; Bai Z; Xiao X
Chin Herb Med; 2022 Jul; 14(3):470-475. PubMed ID: 36117998
[TBL] [Abstract][Full Text] [Related]
2. 8 years post-marketing surveillance between Asari Radix and hepatocellular carcinoma: Nationwide population-based evidence against an association.
Chen CN; Tsai YT; Lai JN
J Ethnopharmacol; 2019 Oct; 243():112094. PubMed ID: 31323301
[TBL] [Abstract][Full Text] [Related]
3. [Rationality of Asari Radix et Rhizoma in Qingfei Paidu Decoction based on literature analysis].
Qin ZN; Wang MX; Shi NN; Wang YP; Zhai HQ
Zhongguo Zhong Yao Za Zhi; 2020 Apr; 45(7):1515-1520. PubMed ID: 32489028
[TBL] [Abstract][Full Text] [Related]
4. Screening epidermal growth factor receptor antagonists from Radix et Rhizoma Asari by two-dimensional liquid chromatography.
Han S; Huang J; Hou J; Wang S
J Sep Sci; 2014 Jul; 37(13):1525-32. PubMed ID: 24740895
[TBL] [Abstract][Full Text] [Related]
5. [Analytical Methods with Qualitative HPLC Fingerprint and Quantitative Measurement of Effective Components of Processed Asari Radix et Rhizoma].
Wang YQ; Jiang XM; Wang Z; Wang W; Liao DF; Yan JY
Zhong Yao Cai; 2015 Jul; 38(7):1388-92. PubMed ID: 26946834
[TBL] [Abstract][Full Text] [Related]
6. Herbal medicine containing aristolochic acid and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection.
Chen CJ; Yang YH; Lin MH; Lee CP; Tsan YT; Lai MN; Yang HY; Ho WC; Chen PC;
Int J Cancer; 2018 Oct; 143(7):1578-1587. PubMed ID: 29667191
[TBL] [Abstract][Full Text] [Related]
7. A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China.
Zhang JY; Dai M; Wang X; Lu WQ; Li DS; Zhang MX; Wang KJ; Dai LP; Han SG; Zhou YF; Zhuang H
Int J Epidemiol; 1998 Aug; 27(4):574-8. PubMed ID: 9758109
[TBL] [Abstract][Full Text] [Related]
8. [The volatile components of three radix et rhizoma asari].
Chen B; Hu SY; Li KW; Cui LJ; Yang JX
Zhong Yao Cai; 2010 Dec; 33(12):1886-93. PubMed ID: 21548367
[TBL] [Abstract][Full Text] [Related]
9. Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection.
Wu HC; Jeng WJ; Pan MH; Hsieh YC; Lu SN; Chen CJ; Yang HI
JHEP Rep; 2022 Feb; 4(2):100410. PubMed ID: 35079699
[TBL] [Abstract][Full Text] [Related]
10. [Quantitative determination of seven major absorbed volatile constituents in mice brain, liver and blood after intragastric administration of Asari Radix et Rhizoma suspension by headspace-solid phase microextraction-gas chromatography-mass spectrometry].
Zhang ZW; Liu GX; Xie DM; Tian F; Jia YK; Xu F; Shang MY; Wang X; Cai SQ
Zhongguo Zhong Yao Za Zhi; 2016 Jan; 41(2):285-293. PubMed ID: 28861975
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study.
Ho CM; Lee CH; Lee MC; Zhang JF; Wang JY; Hu RH; Lee PH
BMC Cancer; 2018 Apr; 18(1):401. PubMed ID: 29631561
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B and C viruses and survival from hepatocellular carcinoma in the Arkhangelsk region: a Russian registry-based study.
Makarova M; Krettek A; Valkov MY; Grjibovski AM
Int J Circumpolar Health; 2013; 72():20282. PubMed ID: 23687637
[TBL] [Abstract][Full Text] [Related]
13.
Lu Y; Hsiang F; Chang JH; Yao XQ; Zhao H; Zou HY; Wang L; Zhang QX
Neural Regen Res; 2018 Jul; 13(7):1195-1203. PubMed ID: 30028327
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of two species of Asari Radix et Rhizoma by electronic nose, headspace GC-MS and chemometrics.
Li C; Xu F; Cao C; Shang MY; Zhang CY; Yu J; Liu GX; Wang X; Cai SQ
J Pharm Biomed Anal; 2013 Nov; 85():231-8. PubMed ID: 23973758
[TBL] [Abstract][Full Text] [Related]
15. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015.
Sun J; Althoff KN; Jing Y; Horberg MA; Buchacz K; Gill MJ; Justice AC; Rabkin CS; Goedert JJ; Sigel K; Cachay E; Park L; Lim JK; Kim HN; Lo Re V; Moore R; Sterling T; Peters MG; Achenbach CJ; Silverberg M; Thorne JE; Mayor AM; Crane HM; Kitahata MM; Klein M; Kirk GD;
JAMA Netw Open; 2021 Feb; 4(2):e2037512. PubMed ID: 33595662
[TBL] [Abstract][Full Text] [Related]
16. Selective serotonin reuptake inhibitors and the risk of hepatocellular carcinoma in hepatitis B virus-infected patients.
Chang CM; Hsieh MS; Yang TC; Hsieh VC; Chiang JH; Huang HH; How CK; Hu SY; Yen DH
Cancer Manag Res; 2017; 9():709-720. PubMed ID: 29238221
[TBL] [Abstract][Full Text] [Related]
17. Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area: a community-based cohort study.
Oh JK; Shin HR; Lim MK; Cho H; Kim DI; Jee Y; Yun H; Yoo KY
BMC Cancer; 2012 Oct; 12():452. PubMed ID: 23039099
[TBL] [Abstract][Full Text] [Related]
18. Association of Heavy Alcohol Intake and ALDH2 rs671 Polymorphism With Hepatocellular Carcinoma and Mortality in Patients With Hepatitis B Virus-Related Cirrhosis.
Tsai MC; Yang SS; Lin CC; Wang WL; Hsu YC; Chen YS; Hu JT; Lin JY; Yu ML; Lin CW
JAMA Netw Open; 2022 Jul; 5(7):e2223511. PubMed ID: 35877121
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic characteristics andoutcomes of hepatocellular carcinoma associated with chronic hepatitis B versus hepatitis C infection.
Aljumah AA; Kuriry H; Faisal N; Alghamdi H
Ann Saudi Med; 2018; 38(5):358-365. PubMed ID: 30284991
[TBL] [Abstract][Full Text] [Related]
20. TNIP1 Polymorphisms with the Risk of Hepatocellular Carcinoma Based on Chronic Hepatitis B Infection in Chinese Han Population.
Cheng Y; Jiang X; Jin J; Luo X; Chen W; Li Q; Zhang C
Biochem Genet; 2019 Feb; 57(1):117-128. PubMed ID: 30073579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
